Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

RNA epigenetic cancer company Accent adds $63M in series B round

Stephen Hansen, Associate Editor
April 23, 2020 9:06 PM UTC
Updated on Apr 23, 2020 at 10:10 PM UTC

Accent has raised $63 million in a series B financing to progress at least one RNA modification program for cancer into the clinic.

Existing investor EcoR1 Capital led the round. New investors GV, AbbVie Ventures, The Mark Foundation for Cancer Research, NS Investment and Droia Ventures also participated, as did existing investors Atlas Venture and The Column Group...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Accent Therapeutics Inc.